Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ACP-211 · 1 trial · 2 indications
The MADRS is a clinician-rated scale that assesses the severity of depressive symptoms. It consists of 10 items, each scored from 0 (no symptoms) to 6 (severe symptoms), resulting in a total score range of 0 to 60. Higher scores indicate greater depression severity.
| Arm | Type | Description |
|---|---|---|
| ACP-211 600 mg | EXPERIMENTAL | ACP-211 600 mg, administered orally twice weekly |
| ACP-211 300 mg | EXPERIMENTAL | ACP-211 300 mg, administered orally twice weekly |
| Placebo | PLACEBO_COMPARATOR | Matching placebo, administered orally twice weekly |
| Name | Type | Description |
|---|---|---|
| ACP-211 | DRUG | ACP-211 monotherapy |
| Placebo | DRUG | Placebo control |
Inclusion Criteria: * Adults ≥18 and ≤65 years of age * Provides written informed consent * Clinical diagnosis of MDD * History of inadequate response to at least two antidepressants, with at least one inadequate response documented during the current episode * Currently treated with an approved an...
Top 20 of 29 competitors
ACP-211 is an investigational small molecule being developed for the treatment of Major Depressive Disorder (MDD). It is currently in Phase 2 clinical development and is being studied in patients with MDD who have had an inadequate response to prior antidepressant therapy.
ACP-211 is being developed by ACADIA Pharmaceuticals Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ACAD. The company is conducting a Phase 2 clinical trial of ACP-211 in the United States.
ACP-211 is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 2 trial is actively recruiting participants to evaluate its safety and efficacy in patients with Major Depressive Disorder.
ACP-211 is being studied in a Phase 2 clinical trial with the identifier NCT07284667. This randomized, double-blind, placebo-controlled trial is evaluating ACP-211 as a monotherapy for Major Depressive Disorder with inadequate antidepressant response. The trial is recruiting 153 participants in the United States.
ACP-211 is a small molecule being developed for Major Depressive Disorder. Its specific molecular target has not been disclosed in available information, so its mechanism of action is not described here.